Malin (DUB:MLC) FCF Margin %: 0.00% (As of Dec. 2024)


What is Malin FCF Margin %?

Malin DUB:MLC FCF Margin % is 0.00% as of Dec. 2024.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Malin's Free Cash Flow for the six months ended in Dec. 2024 was €-0.30 Mil. Malin's Revenue for the six months ended in Dec. 2024 was €0.00 Mil. Therefore, Malin's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Malin's current FCF Yield % is 0.00%.

The historical rank and industry rank for Malin's FCF Margin % or its related term are showing as below:


DUB:MLC's FCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.51
* Ranked among companies with meaningful FCF Margin % only.

Malin FCF Margin % Related Terms

Malin FCF Margin % Historical Data

* Premium members only.

The historical data trend for Malin's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malin FCF Margin % Chart

Malin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Malin Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DUB:MLC vs ZTS, UTHR, VTRS: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Malin's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Malin FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Malin's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Malin's FCF Margin % falls into.


Malin FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Malin's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-1.3/0
= %

Malin's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-0.3/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Malin (DUB:MLC) has a FCF Margin % of 0.00% as of Dec. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Malin and its competitors.
Is Malin's FCF Margin % too high?
Malin's current FCF Margin % is 0.00%.
How does Malin's FCF Margin % compare to ZTS and UTHR?
Malin's FCF Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Malin and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malin's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malin stock overvalued right now?
Malin (DUB:MLC) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Malin (DUB:MLC), the current FCF Margin % is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Malin Business Description

Address 50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.